PolyPeptide Group Balance Sheet Health
Financial Health criteria checks 5/6
PolyPeptide Group has a total shareholder equity of €359.9M and total debt of €91.7M, which brings its debt-to-equity ratio to 25.5%. Its total assets and total liabilities are €665.0M and €305.1M respectively.
Key information
25.5%
Debt to equity ratio
€91.72m
Debt
| Interest coverage ratio | n/a |
| Cash | €48.48m |
| Equity | €359.92m |
| Total liabilities | €305.05m |
| Total assets | €664.97m |
Recent financial health updates
PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt
Oct 21
Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?
Jun 19Recent updates
PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price
Nov 11PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt
Oct 21Sentiment Still Eluding PolyPeptide Group AG (VTX:PPGN)
Sep 16Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?
Jun 19Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce
Mar 14PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price
Mar 13PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 18Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings
Mar 23Financial Position Analysis
Short Term Liabilities: PPGN's short term assets (€292.6M) exceed its short term liabilities (€183.6M).
Long Term Liabilities: PPGN's short term assets (€292.6M) exceed its long term liabilities (€121.4M).
Debt to Equity History and Analysis
Debt Level: PPGN's net debt to equity ratio (12%) is considered satisfactory.
Reducing Debt: PPGN's debt to equity ratio has reduced from 30.5% to 25.5% over the past 5 years.
Debt Coverage: PPGN's debt is well covered by operating cash flow (93%).
Interest Coverage: Insufficient data to determine if PPGN's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 22:17 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PolyPeptide Group AG is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Markus Mayer | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Konstantin Wiechert | Baader Helvea Equity Research |